current
use
vaccin
major
eff
ect
elimin
common
infect
larg
duplic
immun
respons
induc
natur
infect
vaccinolog
face
complex
problem
wane
antibodi
immunosenesc
evas
immun
pathogen
deviat
immun
microbiom
induct
inhibitori
respons
complex
antigen
requir
protect
fortun
vaccin
develop
incorpor
knowledg
immunolog
structur
biolog
system
biolog
synthet
chemistri
meet
challeng
addit
intern
organis
develop
new
fund
licens
pathway
vaccin
aim
pathogen
epidem
potenti
emerg
tropic
area
vaccin
describ
singl
import
health
intervent
human
histori
fi
rst
smallpox
vaccin
conceiv
jenner
develop
idea
attenu
revers
vaccinolog
deriv
capsular
group
b
meningococc
protein
vaccin
requir
protect
longlast
host
immun
respons
vaccin
antigen
safe
handl
administ
broad
coverag
aim
deliv
requir
next
gener
vaccin
develop
draw
major
scientifi
c
advanc
microbiolog
structur
biolog
immunolog
recent
molecular
biolog
howev
despit
huge
success
vaccinolog
date
mani
challeng
remain
involv
scientifi
c
fi
nancial
polit
social
domain
discuss
rang
exampl
impact
child
health
season
infl
uenza
epidem
infect
commonli
caus
infl
uenza
type
b
vaccin
continu
one
effi
caciou
way
prevent
diseas
reduc
morbid
mortal
particularli
vulner
group
despit
vaccin
effi
caci
consid
moder
depend
variabl
includ
vaccin
type
match
circul
strain
vaccin
strain
target
age
group
infl
uenza
viru
consid
highli
variabl
evad
immun
respons
previous
vaccin
popul
current
vaccin
design
induc
product
specifi
c
antibodi
viral
membran
surfac
protein
haemagglutinin
ha
two
infl
uenza
strain
one
two
infl
uenza
b
strain
variat
within
infl
uenza
viru
due
antigen
shift
drift
result
accumul
amino
acid
replac
ha
epitop
lead
mismatch
vaccin
strain
circul
strain
independ
predict
made
year
world
health
organ
live
inactiv
infl
uenza
vaccin
avail
eff
ectiv
vaccin
vulner
group
suboptim
children
inactiv
vaccin
also
reduc
eff
ectiv
compar
live
attenu
vaccin
studi
other
strategi
improv
infl
uenza
vaccin
effi
caci
includ
ad
second
lineag
type
b
high
ha
dose
current
appli
licens
vaccin
strategi
also
describ
test
diff
erent
phase
trial
inactiv
infl
uenza
vaccin
adjuv
licens
canada
young
children
elderli
studi
show
increas
immunogen
vaccin
group
altern
option
includ
ad
tlr
adjuv
like
fl
agellin
ad
conserv
epitop
viral
nucleoprotein
stalk
ha
could
yield
improv
vaccin
effi
caci
genet
vaccin
dna
rna
base
also
contribut
produc
effi
caciou
infl
uenza
vaccin
exampl
alphavirusbas
rna
vaccin
shown
promis
result
although
yet
commerci
avail
sinc
introduct
pertussi
vaccin
incid
pertussi
decreas
dramat
countri
vaccin
given
routin
estim
million
pertussi
case
occur
develop
countri
despit
avail
eff
ectiv
prophylact
vaccin
pertussi
rise
incid
diseas
epidem
throughout
world
last
decad
diff
erent
reason
hypothes
outbreak
wane
immun
vaccin
greater
awar
diseas
report
increas
virul
bacteria
circul
new
strain
true
burden
diseas
industrialis
countri
may
underestim
increas
incid
previous
vaccin
popul
includ
older
children
elderli
advers
reaction
high
fever
sever
irrit
hypoton
hyporespons
episod
sever
local
skin
reaction
describ
administr
whole
cell
vaccin
wp
led
replac
develop
countri
acellular
less
reactogen
vaccin
ap
fi
rst
develop
japan
sever
studi
shown
immun
immunis
pertussi
vaccin
especi
ap
wane
rapidli
studi
koepk
et
al
wisconsin
describ
progress
reduct
ap
vaccin
effi
caci
throughout
year
tabl
immun
mechan
induc
vaccin
may
respons
diff
erenc
natur
infect
immunis
wp
induc
stimul
cell
immun
particular
cell
cell
wherea
ap
vaccin
induc
strong
antibodi
respons
respons
baboon
model
contribut
understand
relev
immun
mechan
follow
natur
infect
vaccin
wp
ap
immun
respons
similar
observ
human
evid
respons
induc
clearanc
b
pertussi
mucos
surfac
therebi
reduc
colonis
transmiss
lack
activ
follow
ap
vaccin
may
account
ongo
diseas
transmiss
resurg
countri
wide
use
ap
vaccin
order
improv
ap
vaccin
effi
caci
possibl
strategi
describ
includ
introduct
strain
contain
promot
new
circul
strain
induc
higher
host
product
pertussi
toxin
pt
provid
possibl
select
advantag
use
new
adjuv
may
may
associ
aluminium
skew
immun
respons
stimul
balanc
respons
like
cpg
oligonucleotid
combin
monophosphoryl
lipid
aluminium
agonist
intervent
use
modifi
ed
bacteria
virul
factor
like
adenyl
cyclas
tracheal
cytotoxin
live
nasal
attenu
pertussi
vaccin
use
recombin
pertussi
dna
vaccin
also
studi
variou
eff
ectiv
method
employ
hiv
prevent
mani
challeng
remain
develop
success
vaccin
uncertainti
protect
function
respons
sinc
natur
recoveri
infect
although
longterm
surviv
possibl
broadli
neutral
antibodi
develop
occur
late
natur
infect
success
vaccin
would
need
induc
rapid
respons
dissemin
mucos
site
infect
take
place
within
hour
protect
respons
would
therefor
rapidli
neutral
viru
mucos
surfac
kill
hivinfect
cell
throughout
bodi
mani
vaccin
hiv
vaccin
would
overcom
strain
variat
current
genet
distinct
clade
subtyp
signifi
cant
variat
within
clade
also
occur
previou
trial
adopt
varieti
approach
obtain
right
function
respons
earli
trial
focus
elicit
neutral
anti
bodi
target
envelop
protein
subsequ
trial
util
viral
vector
deliv
hiv
antigen
includ
canarypox
viru
aim
induc
protect
cellular
immun
respons
includ
primeboost
strategi
use
dna
encod
hiv
protein
follow
recombin
protein
one
studi
demonstr
protect
vaccin
effi
caci
combin
canarypox
vector
vaccin
prime
booster
inject
subunit
vaccin
thailand
reduct
hiv
acquisit
due
induct
antibodi
direct
region
mediat
antibodydepend
cellular
cytotox
adcc
although
effi
caci
high
earli
vaccin
declin
time
import
nonneutr
antibodi
shown
pathogen
notabl
infl
uenza
infect
inactiv
vaccin
induc
adcc
strain
crossreact
antibodi
futur
strategi
hiv
focu
induct
broadli
neutral
antibodi
via
use
envelop
trimer
structur
immunogen
monom
use
better
vector
adjuv
improv
induct
adcc
observ
thailand
trial
induct
eff
ector
memori
cell
direct
noncanon
epitop
use
persist
viral
vector
latter
strategi
eff
ectiv
clearanc
simian
immunodefi
cienci
viru
rhesu
macaqu
use
cmv
vector
may
use
strategi
hiv
chronic
infect
highest
burden
sever
symptomat
rotaviru
diseas
month
old
children
impact
childhood
mortal
signifi
cant
develop
countri
whilst
much
morbid
industrialis
countri
longitudin
studi
identifi
ed
children
natur
infect
rotaviru
develop
adapt
immun
prevent
primari
infect
protect
reinfect
particular
caus
sever
diseas
therefor
principl
administ
oral
live
attenu
rotaviru
strain
develop
current
monoval
human
vaccin
rotarix
pentaval
humanbovin
reassort
vaccin
rotateq
wide
use
rotaviru
vaccin
global
effi
caci
vaccin
high
industrialis
countri
sinc
introduct
us
reduct
hospitalis
emerg
depart
present
allcaus
diarrhoea
attend
rotaviru
hospitalis
unvaccin
individu
suggest
degre
indirect
protect
howev
lower
effi
caci
well
document
mani
develop
countri
clearli
note
vaccin
effi
caci
invers
relationship
childhood
mortal
reason
unclear
propos
explan
includ
presenc
transplacent
breast
milk
deriv
iga
neutralis
eff
ect
concomit
poor
nutrit
chronic
helminth
infect
suppress
immun
respons
howev
microbiota
increasingli
implic
immunolog
develop
modul
infant
mucos
immun
mechan
remain
poorli
understood
although
microbi
interfer
zinc
defi
cienci
appear
import
disturb
resid
microbiota
antibiot
mice
result
reduc
suscept
polioviru
infect
reduc
infect
rotaviru
interestingli
treatment
ampicillin
neomycin
oral
rotaviru
inocul
produc
longer
durat
higher
titr
serum
faecal
iga
compar
untreat
control
intrigu
fi
nding
rais
mani
question
impact
microbiom
composit
mucos
immun
method
immunomodul
eg
probiot
antibiot
could
improv
vaccin
effi
caci
particular
develop
countri
high
mortal
rotaviru
infect
diffi
culti
develop
success
dengu
vaccin
lie
pathogenesi
dengu
hemorrhag
fever
sever
dengu
syndrom
four
dengu
viru
serotyp
infect
result
develop
longlast
serotypespecifi
c
antibodi
contribut
protect
infect
result
lifelong
protect
infect
serotyp
temporari
crossprotect
serotyp
wane
crossneutr
antibodi
later
render
individu
suscept
sever
dengu
event
infect
serotyp
diff
erent
previou
infect
current
one
licens
dengu
vaccin
cydtdv
regist
use
endem
area
individu
age
year
cydtdv
tetraval
vaccin
includ
four
live
recombin
chimer
virus
prm
membran
e
envelop
protein
dengu
viru
serotyp
insert
separ
yellow
fever
genom
vaccin
evalu
clinic
trial
asia
south
america
particip
overal
effi
caci
induc
antibodi
serotyp
effi
caci
vari
depend
serotyp
highest
effi
caci
serotyp
lowest
serotyp
number
explan
diff
ere
serotypespecifi
c
effi
caci
suggest
includ
diff
erent
exposur
dose
diff
erent
serotyp
diff
ere
level
antibodi
need
protect
diff
erent
serotyp
diff
erenc
pathogenesi
serotyp
rapid
infect
monocyt
poor
replic
alter
conform
envelop
protein
chimer
vaccin
serotyp
major
safeti
concern
fi
nding
children
age
year
increas
risk
hospit
two
year
postvaccin
may
due
antibodi
enhanc
eff
ect
similar
seen
wild
type
infect
diff
erent
serotyp
vaccin
recommend
sage
committe
begin
year
age
countri
popul
like
infect
one
dengu
serotyp
age
futur
studi
clarifi
danger
seroneg
particularli
children
human
cytomegaloviru
cmv
dna
herpesviru
preval
seroposit
adult
popul
high
viru
respons
lifelong
latent
infect
despit
high
seroposit
cmv
congenit
infect
due
primari
infect
reinfect
realiti
eff
ectiv
prevent
strategi
current
avail
infect
popul
reactiv
normal
occur
immunocompromis
host
associ
sever
outcom
whole
organ
stem
cell
transplant
recipi
cmv
infect
consid
one
common
associ
acut
infect
long
term
indirect
eff
ect
could
contribut
allograft
injuri
subsequ
graft
loss
implement
cmv
vaccin
could
decreas
diseas
burden
signifi
cant
econom
impact
sever
vaccin
candid
develop
one
fi
rst
cmv
vaccin
wide
test
human
particularli
renal
transplant
patient
develop
stanley
plotkin
laboratori
one
author
paper
contain
town
strain
reduc
sever
diseas
seroneg
renal
transplant
patient
although
result
consid
signifi
cant
infect
howev
vaccin
success
protect
seroneg
mother
acquir
infect
young
children
recent
subunit
vaccin
develop
glycoprotein
b
gb
antibodi
specifi
c
present
cmv
seroposit
individu
current
use
new
vaccin
design
includ
gb
adjuv
gbcanarypox
vector
dna
vaccin
trival
dna
vaccin
bival
dna
vaccin
cmv
vaccin
candid
includ
replicationdefect
cmv
strain
solubl
pentam
protein
replicationdefect
adenoviru
vector
alphaviru
replicon
dens
bodi
selfrepl
rna
vaccin
respiratori
syncyti
viru
rsv
import
caus
infant
hospitalis
develop
countri
global
respons
death
infant
malaria
clearli
urgent
need
eff
ectiv
vaccin
develop
formalininactiv
rsv
firsv
vaccin
protect
primari
rsv
infect
paradox
result
sever
clinic
diseas
particular
young
vaccin
children
firsv
vaccin
fail
due
alter
fusion
f
protein
formalin
treatment
result
imbalanc
host
respons
immun
complex
deposit
skew
f
glycoprotein
remain
main
antigen
target
rsv
vaccin
develop
due
role
host
cell
viral
entri
conserv
across
b
subtyp
abil
antif
passiv
monoclon
antibodi
palivizumab
prevent
sever
diseas
rsv
infant
human
sera
neutralis
activ
pref
metast
epitop
much
greater
postf
stabl
requir
intric
understand
atomiclevel
protein
structur
order
stabilis
convers
vaccin
candid
use
prefspecifi
c
monoclon
antibodi
bind
pref
crystal
structur
visualis
identifi
novel
antigen
site
avail
postf
due
conform
chang
occur
membran
fusion
allow
viral
entri
figur
optim
stabilis
pref
achiev
insert
cystein
residu
form
disulphid
bond
caviti
fi
lling
mutat
result
stabl
pref
induc
potent
neutralis
antibodi
mice
macaqu
molecular
approach
rapidli
appli
synthet
vaccin
develop
identifi
cation
suitabl
candid
antigen
understand
b
cell
repertoir
lead
structur
antigen
modifi
cation
effi
caci
current
pref
vaccin
clinic
trial
yet
demonstr
mani
rsv
vaccin
clinic
trial
due
previou
safeti
concern
impact
passiv
matern
antibodi
vaccin
effi
caci
direct
protect
infant
prioriti
altern
vaccin
strategi
involv
immunis
pregnant
women
passiv
transfer
neutralis
antibodi
protect
infant
month
age
immunis
older
children
protect
disrupt
transmiss
immunis
elderli
provid
direct
protect
vulner
group
approach
show
promis
clinic
trial
includ
extend
halflif
monoclon
antibodi
direct
prefus
f
protein
potenti
provid
passiv
immun
one
intramuscular
dose
per
season
healthi
highrisk
infant
fi
rst
rsv
season
sever
aspect
relat
vaccin
design
understand
vaccineinduc
immun
import
investig
come
year
number
new
technolog
develop
preclin
studi
improv
futur
vaccin
dna
plasmid
without
electropor
selfamplifi
mrna
molecul
vaccin
better
abl
activ
dendrit
cell
nonspecifi
c
eff
ect
vaccin
far
understood
may
consequ
reach
beyond
fi
eld
vaccinolog
vaccin
antigen
abl
shape
immun
system
earli
life
reduct
speed
cost
genet
sequenc
mean
becom
easier
use
genet
inform
vaccin
individu
better
predict
immunogen
reactogen
vaccin
aid
futur
vaccin
design
persist
vaccineinduc
protect
remain
issu
almost
vaccin
requir
multipl
dose
may
improv
futur
better
understand
role
follicular
cell
induct
protect
respons
possibl
role
improv
persist
protect
pathogen
multipl
virul
antigen
could
includ
vaccin
understand
natur
immun
respons
diff
erenc
respons
individu
infect
aid
antigen
select
identifi
cation
conserv
epitop
may
help
design
vaccin
univers
protect
pathogen
although
diffi
cult
achiev
date
vaccin
still
defi
ned
correl
protect
newer
system
biolog
approach
may
abl
character
like
complex
depend
number
factor
rather
singl
cutoff
valu
antibodi
assay
better
adjuv
requir
improv
respons
immatur
immun
system
infant
immunocompromis
specifi
calli
stimul
select
respons
gener
cell
immun
absenc
vaccin
replic
financi
constraint
pharmaceut
compani
may
result
reduc
vaccin
develop
product
nation
public
health
bodi
stipul
prioriti
industri
develop
combin
time
frame
concept
licensur
inevit
delay
lack
cohes
lack
enthusiasm
econom
incent
invest
vaccin
emerg
diseas
fl
avivirus
zika
west
nile
haemorrhag
fever
ebola
marburg
lassa
coronavirus
mer
sar
howev
expans
develop
countri
vaccin
manufactur
network
encourag
sustain
aff
ordabl
vaccin
product
recent
chang
patent
protect
drug
manufactur
develop
region
may
help
amelior
issu
collect
respons
respons
recent
largescal
global
epidem
led
establish
coalit
epidem
prepar
innov
januari
multifacet
partnership
involv
govern
industri
civil
bodi
foundat
focu
vaccin
develop
potenti
epidem
infect
challeng
lie
prioritis
infect
organis
develop
manufactur
process
obtain
sustain
fund
arrang
govern
foundat
host
vaccin
must
safe
minim
side
eff
ect
must
provok
immun
respons
specifi
citi
memori
induc
longlast
protect
ideal
quantifi
ed
context
vaccine
resid
may
impact
abil
respond
vaccin
antigen
demograph
environment
condit
vaccin
antigen
abl
captur
divers
pathogen
organ
welldefi
ned
structur
method
enhanc
recognit
host
ultim
easili
reproduc
mass
product
hostpathogen
interact
molecular
cellular
level
play
import
role
develop
futur
vaccin
continu
aspir
develop
vaccin
excel
immunogen
extrem
age
protect
divers
array
pathogen
organ
ultim
avail
popul
cmcr
mvp
confl
ict
interest
ms
investig
grant
award
pfi
zer
receiv
person
payment
sp
paid
consult
major
vaccin
manufactur
number
biotechnolog
compani
work
vaccin
develop
